{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:39:42Z","timestamp":1787445582113,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravitreally administered biotherapeutics can elicit local and systemic immune responses with potentially serious clinical consequences. However, little is known about the mechanisms of ocular antidrug immune response, the incidence of ocular antidrug antibodies (ADAs), and the relationship between ocular and systemic ADA levels. Bioanalytical limitations and poor availability of ocular matrices make studies of ocular immunogenicity particularly challenging. We have recently reported a novel bioanalytical ADA assay and shown its applicability for the ADA detection in ocular matrices. In the present study, we used this assay to analyze a large set of preclinical samples from minipig and cynomolgus monkeys treated with different ocular biotherapeutics. We found a significant association between the incidence of ADAs in plasma and ocular fluids after a single intravitreal administration of the drugs. Importantly, none of the animals with ADA-negative results in plasma had detectable ADAs in ocular fluids and systemic ADA response always preceded the appearance of ocular ADAs. Overall, our results suggest the systemic origin of ocular ADAs and support the use of plasma as a surrogate matrix for the detection of ocular ADA response.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1208\/s12248-022-00766-2","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T01:27:20Z","timestamp":1669166840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical Observations of Systemic and Ocular Antidrug Antibody Response to Intravitreally Administered Drugs"],"prefix":"10.1208","volume":"25","author":[{"given":"Uwe","family":"Wessels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zadak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Manuela","family":"Weidmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stuchly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay-Gunnar","family":"Stubenrauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"766_CR1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/cts.2020.493","volume":"4","author":"TC Vandivort","year":"2020","unstructured":"Vandivort TC, Horton DB, Johnson SB. Regulatory and strategic considerations for addressing immunogenicity and related responses in biopharmaceutical development programs. J Clin Transl Sci. 2020;4:547\u201355.","journal-title":"J Clin Transl Sci"},{"key":"766_CR2","unstructured":"Guideline on Immunogenicity assessment of therapeutic proteins. European Medicines Agency, Committee for Medicinal Products for Human Use; 2017 [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed Oct 2022"},{"key":"766_CR3","unstructured":"Immunogenicity assessment for therapeutic protein products. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration; 2014 [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.fda.gov\/media\/85017\/download.\u00a0Accessed Oct 2022"},{"key":"766_CR4","doi-asserted-by":"crossref","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti\u2010vascular endothelial growth factor for neovascular age\u2010related macular degeneration. Cochrane Db Syst Rev. 2019;2019:CD005139.","DOI":"10.1002\/14651858.CD005139.pub4"},{"key":"766_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/OPTH.S169143","volume":"12","author":"S Kiss","year":"2018","unstructured":"Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol Auckl N Z. 2018;12:1625\u201335.","journal-title":"Clin Ophthalmol Auckl N Z"},{"key":"766_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","volume":"23","author":"EH Souied","year":"2016","unstructured":"Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis. Ophthalmic Epidemiol. 2016;23:71\u20139.","journal-title":"Ophthalmic Epidemiol"},{"key":"766_CR7","unstructured":"BEOVU. Prescribing information. Novartis Pharmaceuticals Corporation; 2022. [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761125s008lbl.pdf.\u00a0Accessed Oct 2022"},{"key":"766_CR8","unstructured":"LUCENTIS. Prescribing information. Genentech, Inc; 2018. [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125156s117lbl.pdf.\u00a0Accessed Oct 2022"},{"key":"766_CR9","doi-asserted-by":"crossref","unstructured":"Busch M, Pfeil JM, D\u00e4hmcke M, Brauckmann T, Gro\u00dfjohann R, Chisci V, et al. Anti\u2010drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease. Acta Ophthalmol. 2022;","DOI":"10.1111\/aos.15124"},{"key":"766_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","volume":"7","author":"WJ Anderson","year":"2021","unstructured":"Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retin Vitreous. 2021;7:37.","journal-title":"Int J Retin Vitreous"},{"key":"766_CR11","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41433-020-0853-9","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, et al. Brolucizumab and immunogenicity Eye. 2020;34:1726\u20138.","journal-title":"Brolucizumab and immunogenicity Eye"},{"key":"766_CR12","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1208\/s12248-017-0128-y","volume":"19","author":"E Wakshull","year":"2017","unstructured":"Wakshull E, Quarmby V, Mahler H-C, Rivers H, Jere D, Ramos M, et al. Advancements in understanding immunogenicity of biotherapeutics in the intraocular space. Aaps J. 2017;19:1656\u201368.","journal-title":"Aaps J"},{"key":"766_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fimmu.2012.00296","volume":"3","author":"I Benhar","year":"2012","unstructured":"Benhar I, London A, Schwartz M. The privileged immunity of immune privileged organs: the case of the eye. Front Immunol. 2012;3:296.","journal-title":"Front Immunol"},{"key":"766_CR14","unstructured":"EYLEA. Prescribing information. Regeneron Pharmaceuticals, Inc.; 2021. [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125387s069lbl.pdf.\u00a0Accessed Oct 2022"},{"key":"766_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ajo.2004.05.028","volume":"138","author":"M Inoue","year":"2004","unstructured":"Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138:1046\u20138.","journal-title":"Am J Ophthalmol"},{"key":"766_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2020.104825","volume":"119","author":"TK MacLachlan","year":"2021","unstructured":"MacLachlan TK, Kronenberg S, Marshall N, Andrews L, Berens SJ, Brouta F, et al. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies. Regul Toxicol Pharm. 2021;119: 104825.","journal-title":"Regul Toxicol Pharm"},{"key":"766_CR17","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s11095-011-0523-5","volume":"28","author":"V Brinks","year":"2011","unstructured":"Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: The Use of Animal Models. Pharmaceut Res. 2011;28:2379\u201385.","journal-title":"Pharmaceut Res"},{"key":"766_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.4155\/bio-2018-0047","volume":"10","author":"U Wessels","year":"2018","unstructured":"Wessels U, Zadak M, Reiser A, Brockhaus J, Ritter M, Abdolzade-Bavil A, et al. Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. Bioanalysis. 2018;10:803\u201314.","journal-title":"Bioanalysis"},{"key":"766_CR19","unstructured":"Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration; 2019 [Internet]. [cited 2022 Aug 1]. Available from: https:\/\/www.fda.gov\/media\/119788\/download.\u00a0Accessed Oct 2022"},{"key":"766_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1874364101004010052","volume":"4","author":"M Goel","year":"2010","unstructured":"Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52\u20139.","journal-title":"Open Ophthalmol J"},{"key":"766_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.2042-3306.1986.tb03562.x","volume":"18","author":"A Matthews","year":"1986","unstructured":"Matthews A, Poulter T. Albumin and immunoglobulins G, A and M in aqueous humour from clinically normal equine eyes. Equine Vet J. 1986;18:117\u201320.","journal-title":"Equine Vet J"},{"key":"766_CR22","first-page":"120","volume":"99","author":"AR Fielder","year":"1979","unstructured":"Fielder AR, Rahi AH. Immunoglobulins of normal aqueous humour. T Ophthal Soc Uk. 1979;99:120\u20135.","journal-title":"T Ophthal Soc Uk"},{"key":"766_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjo.61.3.216","volume":"61","author":"DK Sen","year":"1977","unstructured":"Sen DK, Sarin GS, Saha K. Immunoglobulins in human aqueous humour. Brit J Ophthalmol. 1977;61:216.","journal-title":"Brit J Ophthalmol"},{"key":"766_CR24","doi-asserted-by":"crossref","unstructured":"Garweg JG, Garweg S-DL, Flueckiger F, Jacquier P, Boehnke M. Aqueous humor and serum immunoblotting for immunoglobulin Types G, A, M, and E in Cases of Human Ocular Toxoplasmosis. J Clin Microbiol. 2004;42:4593\u20138.","DOI":"10.1128\/JCM.42.10.4593-4598.2004"},{"key":"766_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1463-5224.2012.01010.x","volume":"15","author":"JK Zipplies","year":"2012","unstructured":"Zipplies JK, Hauck SM, Eberhardt C, Hirmer S, Amann B, Stangassinger M, et al. Miscellaneous vitreous-derived IgM antibodies target numerous retinal proteins in equine recurrent uveitis. Vet Ophthalmol. 2012;15:57\u201364.","journal-title":"Vet Ophthalmol"},{"key":"766_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jcjo.2019.11.010","volume":"55","author":"J Rullo","year":"2020","unstructured":"Rullo J, Bae S, Far PM, Hazimi AA, Gupta V, Bal M, et al. Measuring intraocular antibodies in eyes treated with anti-vascular endothelial growth factor. Can J Ophthalmology. 2020;55:263\u201371.","journal-title":"Can J Ophthalmology"},{"key":"766_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4155\/bio-2020-0143","volume":"12","author":"G Jordan","year":"2020","unstructured":"Jordan G, Staack RF. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody\u2013reagent complexes at cut-point (CP-ARC) the missing piece? Bioanalysis. 2020;12:1021\u201331.","journal-title":"Bioanalysis"},{"key":"766_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0192623318770379","volume":"46","author":"SM Shrader","year":"2018","unstructured":"Shrader SM, Greentree WF. G\u00f6ttingen minipigs in ocular research. Toxicol Pathol. 2018;46:403\u20137.","journal-title":"Toxicol Pathol"},{"key":"766_CR29","doi-asserted-by":"crossref","unstructured":"Cauvin AJ, Peters C, Brennan F. The nonhuman primate in nonclinical drug development and safety assessment. Vii Nonhum Primate-specific Aspects Stand Toxicol Stud. 2015;379\u201395.","DOI":"10.1016\/B978-0-12-417144-2.00019-6"},{"key":"766_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4155\/bio-2020-0308","volume":"13","author":"C K\u00fcnzel","year":"2021","unstructured":"K\u00fcnzel C, Abdolzade-Bavil A, Engel AM, Pleitner M, Schick E, Stubenrauch K. Assay concept for detecting anti-drug IgM in human serum samples by using a novel recombinant human IgM positive control. Bioanalysis. 2021;13:253\u201363.","journal-title":"Bioanalysis"},{"key":"766_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4155\/bio-2022-0085","volume":"14","author":"A P\u00f6hler","year":"2022","unstructured":"P\u00f6hler A, Emrich T, Jordan G, Sch\u00e4fer M, Stubenrauch K-G, Staack RF, et al. Comparison of assay formats used for the detection of pre-existing anti-drug antibodies against monoclonal antibodies. Bioanalysis. 2022;14:923\u201333.","journal-title":"Bioanalysis"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-022-00766-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-022-00766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:03:20Z","timestamp":1677081800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-022-00766-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1208\/s12248-022-00766-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Animals"}},{"value":"The authors are employees of Roche Diagnostics GmbH, Penzberg, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"2"}}